Grufity logoGrufity logo

Johnson & Johnson Stock Research

JNJ

151.02USD-0.03(-0.02%)Market Closed

Market Summary

USD151.02-0.03
Market Closed
-0.02%

JNJ Alerts

JNJ Stock Price

JNJ RSI Chart

JNJ Valuation

Market Cap

396.9B

Price/Earnings (Trailing)

22.12

Price/Sales (Trailing)

4.18

EV/EBITDA

13.21

Price/Free Cashflow

23.09

JNJ Price/Sales (Trailing)

JNJ Profitability

EBT Margin

22.88%

Return on Equity

23.36%

Return on Assets

9.57%

Free Cashflow Yield

4.33%

JNJ Fundamentals

JNJ Revenue

Revenue (TTM)

94.9B

Revenue Y/Y

-4.43%

Revenue Q/Q

-0.36%

JNJ Earnings

Earnings (TTM)

17.9B

Earnings Y/Y

-25.68%

Earnings Q/Q

-21.04%

Price Action

52 Week Range

150.15183.08
(Low)(High)

Last 7 days

-1.9%

Last 30 days

-4.4%

Last 90 days

-14.9%

Trailing 12 Months

-11.7%

JNJ Financial Health

Current Ratio

0.99

Debt/Equity

0.42

Debt/Cashflow

0.73

JNJ Investor Care

Dividend Yield

2.95%

Dividend/Share (TTM)

4.45

Buy Backs (1Y)

0.18%

Diluted EPS (TTM)

6.73

Peers (Alternatives to Johnson & Johnson)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
396.9B
94.9B
-4.42% -11.67%
22.12
4.18
1.25% -14.07%
298.8B
28.5B
1.30% 17.85%
47.85
10.47
0.79% 11.88%
272.8B
59.3B
-5.09% 32.83%
17.88
4.63
21.72% 11.27%
226.2B
100.3B
-5.50% -20.78%
7.21
2.25
23.43% 42.74%
142.4B
46.2B
-5.97% -4.10%
22.5
3.08
-0.49% -9.54%
MID-CAP
4.5B
4.5B
-8.55% -11.11%
-32.05
1.01
7.56% -104.06%
3.2B
2.2M
109.33% 133.59%
-10.15
1.4K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-10.48% 10.28%
30.48
2.77
15.09% 13.64%
1.6B
602.5M
-5.76% -54.20%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-20.83% -73.20%
-0.29
1.93
-31.50% -634.70%
772.8M
285.2M
-9.04% -42.36%
3.51
2.71
-27.21% -40.28%
726.9M
114.5M
-12.79% -47.96%
-4.31
6.35
27.90% 57.40%
539.5M
29.8M
-36.94% -53.16%
-6.21
18.13
340.05% 4.35%
379.1M
51.5M
-14.46% -5.94%
-5.34
7.36
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Johnson & Johnson

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.1%94,94396,04195,58894,88093,775
Gross Profit-1.4%63,85464,76264,86664,49063,920
  S&GA Expenses-2.5%24,76525,40725,31825,16524,659
EBITDA-2.0%28,97129,56027,68528,604-
EBITDA Margin-0.9%0.31*0.31*0.29*0.30*-
Earnings Before Taxes-2.8%21,72522,36020,38721,20922,776
EBT Margin-1.7%0.23*0.23*0.21*0.22*-
Interest Expenses73.6%276159128130183
Net Income-6.3%17,94119,15718,36619,83020,878
Net Income Margin-5.3%0.19*0.20*0.19*0.21*-
Free Cahsflow-3.1%17,18517,73919,95019,733-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets7.0%187,378175,124177,724178,355182,018
  Current Assets-15.2%55,29465,23663,84760,42460,979
    Cash Equivalents24.4%14,12711,35510,98310,46314,487
  Inventory6.9%12,48311,67511,43710,99010,387
  Net PPE9.1%19,80318,15218,35418,70118,962
  Goodwill35.5%45,23133,38334,16634,93535,246
Liabilities10.0%110,574100,525101,367103,646107,995
  Current Liabilities22.5%55,80245,54344,82143,39045,226
.    Short Term Borrowings188.7%12,7714,4244,3054,2973,766
  Long Term Debt-32,116----
    LT Debt, Current-2,131----
    LT Debt, Non Current-2.6%26,88827,60328,29228,85129,985
Shareholder's Equity3.0%76,80474,59976,35774,70974,023
  Retained Earnings0.3%128,345127,917126,216124,380123,060
Accumulated Depreciation-0.9%28,52928,79029,00128,717-
Shares Outstanding-0.1%2,6282,6302,629--
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-1.8%21,19421,57623,58223,31523,410
  Share Based Compensation-0.2%1,1381,1401,1181,1061,135
Cashflow From Investing7.2%-12,371-13,334-14,352-12,132-8,683
Cashflow From Financing36.7%-8,871-14,007-12,289-13,307-14,047
  Buy Backs5.7%6,0355,7113,9373,5953,456

Risks for JNJ

What is the probability of a big loss on JNJ?

17.7%


Probability that Johnson & Johnson stock will be more than 20% underwater in next one year

0%


Probability that Johnson & Johnson stock will be more than 30% underwater in next one year.

0%


Probability that Johnson & Johnson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JNJ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Johnson & Johnson was unfortunately bought at previous high price.

Drawdowns

Returns for JNJ

Cumulative Returns on JNJ

9.5%


10-Year Cumulative Returns

7.6%


7-Year Cumulative Returns

6.5%


5-Year Cumulative Returns

13.4%


3-Year Cumulative Returns

What are the long-term rolling returns for JNJ?

FIve years rolling returns for Johnson & Johnson.

Annualized Returns

Which funds bought or sold JNJ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
3.92
3,092,040
29,398,000
0.82%
2023-03-14
AWM CAPITAL, LLC
added
4.65
19,854
492,854
0.17%
2023-03-13
Claro Advisors LLC
added
11.7
325,670
3,244,670
1.06%
2023-03-10
BAILLIE GIFFORD & CO
added
9.09
3,078
19,078
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-3.08
23,020,400
502,397,000
0.55%
2023-03-10
MATHER GROUP, LLC.
added
4.4
543,679
4,761,680
0.09%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
added
0.04
178,338
2,361,340
0.37%
2023-03-08
Capital Asset Advisory Services LLC
added
3.73
413,385
3,381,380
0.27%
2023-03-07
Great Lakes Retirement, Inc.
new
-
1,239,020
1,239,020
0.32%
2023-03-07
Nordwand Advisors, LLC
new
-
188,939,000
188,939,000
23.56%

1–10 of 48

Latest Funds Activity

Are funds buying JNJ calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own JNJ
No. of Funds

Johnson & Johnson News

InvestorsObserver

Where Will Johnson & Johnson (JNJ) Stock Go Next After It Is Down 2.43% in a Week?.

InvestorsObserver,
7 hours ago

Pulse 2.0

InvestorsObserver

InvestorsObserver

InvestorsObserver

InvestorPlace

Investor's Business Daily

Schedule 13G FIlings of Johnson & Johnson

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.44%
246,826,621
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
198,802,769
SC 13G/A
Feb 14, 2022
state street corp
5.51%
144,996,127
SC 13G/A
Feb 10, 2022
vanguard group inc
8.92%
234,782,632
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
200,021,352
SC 13G/A
Feb 12, 2021
state street corp
5.47%
144,029,634
SC 13G
Feb 10, 2021
vanguard group inc
8.66%
227,946,104
SC 13G/A
Jan 29, 2021
blackrock inc.
7.2%
188,510,542
SC 13G/A
Feb 13, 2020
state street corp
5.77%
151,867,233
SC 13G
Feb 12, 2020
vanguard group inc
8.67%
228,297,775
SC 13G/A

JNJ Fair Value

Johnson & Johnson fair value in different scenarios

The table shows the Fair Value estimates for Johnson & Johnson for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

71.21

-52.85%

93.65

-37.99%

134.05

-11.24%

169.21

12.04%

199.06

31.81%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Johnson & Johnson Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Johnson & Johnson

View All Filings
Date Filed Form Type Document
Mar 22, 2023
PX14A6G
PX14A6G
Mar 16, 2023
ARS
ARS
Mar 15, 2023
DEF 14A
DEF 14A
Mar 15, 2023
DEFA14A
DEFA14A
Mar 15, 2023
DEFA14A
DEFA14A
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Feb 22, 2023
3
Insider Trading
Feb 16, 2023
10-K
Annual Report

Latest Insider Trading transactions for JNJ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-06
Swanson James D.
sold
-164,199
154
-1,061
see remarks
2023-02-13
Wengel Kathryn E
acquired
-
-
10,839
evp, chief to and risk officer
2023-02-13
Mongon Thibaut
acquired
-
-
13,710
exec vp, ww chair, cons health
2023-02-13
Duato Joaquin
sold (taxes)
-2,203,170
162
-13,599
ceo and chairman of the board
2023-02-13
Fasolo Peter
acquired
-
-
12,468
exec vp, chief hr officer
2023-02-13
Hait William
acquired
-
-
9,640
see remarks
2023-02-13
Hait William
sold (taxes)
-742,978
162
-4,586
see remarks
2023-02-13
Forminard Elizabeth
acquired
-
-
2,555
executive vp, general counsel
2023-02-13
Wolk Joseph J
sold (taxes)
-1,389,720
162
-8,578
exec vp, cfo
2023-02-13
Broadhurst Vanessa
acquired
-
-
3,981
evp, global corp affairs

1–10 of 50

Joaquin Duato
65535
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

JNJ Income Statement

2023-01-01
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Income Statement [Abstract]   
Sales to customers$ 94,943$ 93,775$ 82,584
Cost of products sold31,08929,85528,427
Gross profit63,85463,92054,157
Selling, marketing and administrative expenses24,76524,65922,084
Research and development expense14,60314,71412,159
In-process research and development (Note 5)783900181
Interest income(490)(53)(111)
Interest expense, net of portion capitalized (Note 4)276183201
Other (income) expense, net1,8714892,899
Restructuring (Note 20)321252247
Earnings before provision for taxes on income21,72522,77616,497
Provision for taxes on income (Note 8)3,7841,8981,783
Net earnings$ 17,941$ 20,878$ 14,714
Net earnings per share (Notes 1 and 15)   
Basic (in dollars per share)$ 6.83$ 7.93$ 5.59
Diluted (in dollars per share)$ 6.73$ 7.81$ 5.51
Average shares outstanding (Notes 1 and 15)   
Basic (in shares)2,625.22,632.12,632.8
Diluted (in shares)2,663.92,674.02,670.7

JNJ Balance Sheet

2023-01-01
Consolidated Balance Sheets - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Current assets:  
Cash and cash equivalents (Notes 1 and 2)$ 14,127$ 14,487
Marketable securities (Notes 1 and 2)9,39217,121
Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)16,16015,283
Inventories (Notes 1 and 3)12,48310,387
Prepaid expenses and other receivables3,1323,701
Total current assets55,29460,979
Property, plant and equipment, net (Notes 1 and 4)19,80318,962
Intangible assets, net (Notes 1 and 5)48,32546,392
Goodwill (Notes 1 and 5)45,23135,246
Deferred taxes on income (Note 8)9,12310,223
Other assets9,60210,216
Total assets187,378182,018
Current liabilities  
Loans and notes payable (Note 7)12,7713,766
Accounts payable11,70311,055
Accrued liabilities11,45613,612
Accrued rebates, returns and promotions14,41712,095
Accrued compensation and employee related obligations3,3283,586
Accrued taxes on income (Note 8)2,1271,112
Total current liabilities55,80245,226
Long-term debt (Note 7)26,88829,985
Deferred taxes on income (Note 8)6,3747,487
Employee related obligations (Notes 9 and 10)6,7678,898
Long-term taxes payable (Note 1)4,3065,713
Other liabilities10,43710,686
Total liabilities110,574107,995
Commitments and Contingencies (Note 19)
Shareholders’ equity  
Preferred stock — without par value (authorized and unissued 2,000,000 shares)00
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)3,1203,120
Accumulated other comprehensive income (loss) (Note 13)(12,967)(13,058)
Retained earnings128,345123,060
Stockholders' Equity before Treasury Stock118,498113,122
Less: common stock held in treasury, at cost (Note 12) (506,246,000 shares and 490,878,000 shares)41,69439,099
Total shareholders’ equity76,80474,023
Total liabilities and shareholders’ equity$ 187,378$ 182,018